Heidelberg Pharma AG · XETR:HPHA
Heidelberg Pharma — German Equity Forum / EKF 2020
26 slides from Heidelberg Pharma's conference presentation, November 2020
Slide 1: ATACs: a Unique New Mode of Action to Fight Cancer
ATACs: a Unique New Mode of Action to Fight Cancer German Equity Forum / EKF, November 2020 © Heidelberg Pharma AG
Slide 2: Safe Harbor
Safe Harbor Forward looking statements This communication contains certain forward-looking statements, product liability and limitations of insurance, limitations of supplies, relating to the Company’s business, which can be identified by the use of competition from other biopharmaceutical, chemical
Slide 3: Corporate Overview
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 3
Slide 4: Heidelberg Pharma at a Glance
Heidelberg Pharma at a Glance Developing new options to address major challenges in cancer therapy Our Company Our Mission Our Approach Listed as Heidelberg Pharma AG New option in cancer therapy with Inhibition of RNA Polymerase II Frankfurt Stock Exchange: HPHA a unique mode of action Amanitin as
Slide 5: Management Team with Strong Pharma and R&D Experience
Management Team with Strong Pharma and R&D Experience Dr. Jan Schmidt-Brand Prof. Dr. Andreas Pahl CEO / CFO CSO @ Heidelberg Pharma since 2001 @ Heidelberg Pharma since 2012 30 years’ experience in commercial and financial leadership positions in pharma Professor of Pharmacology and Toxicology at t
Slide 6: Technology & Validation
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Financials & Outlook © Heidelberg Pharma AG 6
Slide 7: Antibody Targeted Amanitin Conjugates (ATACs)
Antibody Targeted Amanitin Conjugates (ATACs) Combining the Best of Two Therapeutic Modalities ATAC = ADC with Amanitin as toxic payload Comprehensive IP protection Highly specific antibody • Chemical synthesis of toxins, • Antibodies for different tumor targets • Optimal linker attachment sites, •
Slide 8: ATACs Fill the Gap – the Missing MoA of Cancer Chemotherapeutics
Amanitin – the only currently known inhibitor of RNA polymerase II ATACs Fill the Gap – the Missing MoA of Cancer Chemotherapeutics Amanitin – novel mode of action for cancer therapy Purines and pyrimidines 6-Mercaptopurine (Inhibit syntheses) Amanitin specifically binds and inhibits Ribonucleotides
Slide 9: Business Model
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 9
Slide 10: Strategic Cornerstones
Strategic Cornerstones Build proprietary ATAC Licensed legacy assets ATAC pipeline collaborations (non-ATACs) HDP-101 – ATAC targeted against BCMA Licensing collaborations with Additional upside potential (multiple myeloma) pharma and biotech from clinical programs Up to USD 113 million TLX250-CDx –
Slide 11: Growing Pipeline of Proprietary and Partnered Programs
Growing Pipeline of Proprietary and Partnered Programs Product Target Indication Research Preclinic Clinic Partner Proprietary ATAC pipeline I II III HDP-101 BCMA Multiple myeloma (DLBCL/CLL) Proprietary HDP-102 CDXX NHL Proprietary HDP-103 PSMA Prostate cancer Proprietary XX-ATACs n/a Solid / Hemat
Slide 12: ADCs: Selected Deals in 2020
ADCs: Selected Deals in 2020 Merck & Co. AstraZeneca signs deal acquires VelosBio with Daiichi Sankyo for US$2.75 bn worth US$6 bn Phase I ADC VLS-101 Rights to a Phase I ADC DS-1062 Two ADCs and a bispecific antibody in preclinical Joint development and development commercialization Gilead Sciences
Slide 13: Proprietary ATAC Projects
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Financials & Outlook © Heidelberg Pharma AG 13
Slide 14: Multiple Myeloma Major Unmet Medical Need
Multiple Myeloma Major Unmet Medical Need • Second most prevalent hematopoietic malignancy* Myeloma cells are • 70,000 deaths due to MM annually; median age at diagnosis is located in the bone marrow and grow 65-70 years there • Malignancy characterized by the proliferation of single clone Healthy S
Slide 15: ATACs Kill Dormant Tumor Cells
ATACs Kill Dormant Tumor Cells Lead Candidate HDP-101 Ex-vivo Model Comparison of anti-BCMA-ATAC (HDP-101) with MMAF (Auristatin Conjugate as used by GSK) on MM Patient Cells Non-dividing (quiescent) cells isolated from multiple myeloma patients bone marrow biopsies Dividing tumor cells from lab cel
Slide 16: 17p Deletion – Use of Biomarker for Accelerated Clinical Development
17p Deletion – Use of Biomarker Could Provide Opportunity for Accelerated Clinical Development Case study: HDP-101 for multiple myeloma Overall survival of MM patients with and without 17p deletion • MM patients with 17p deleted tumors have a very high medical need for new treatment options Lower su
Slide 17: HDP-101 has best-in-class potential for relapsed/refractory multiple myeloma
HDP-101 has best-in-class potential for relapsed / refractory multiple myeloma Unique preclinical features of HDP-101 Potential clinical benefit Efficacious on dormant tumor cells Longer PFS and MRD negativity Efficacious in ultra-low BCMA tumor cells Deeper responses and higher ORR Novel MoA to whi
Slide 18: Partnered Projects
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 18
Slide 19: Partner Magenta Making Important Progress in ATAC Programs for Conditioning
Partner Magenta Making Important Progress in ATAC Programs for Conditioning Conditioning: ATAC-mediated Stem cell depletion before stem cell conditioning transplants or gene therapies Current regimen: Harsh chemotherapy or irradiation Magenta‘s approach: ATAC-mediated conditioning Collaboration enab
Slide 20: Legacy Assets Licensed to Partner Telix
Legacy Assets Licensed to Partner Telix – Imaging Agent TLX250-CDx and Therapeutic Agent TLX250 TLX250-CDx – diagnostic agent TLX250 – therapeutic agent 89Zirconium labelled girentuximab 177Lu-DOTA labelled girentuximab Benign • Non-invasive detection and staging • Therapeutic radioimmunoconjugate f
Slide 21: Legacy Asset Licensed to Partner RedHill – RHB-107
Legacy Asset Licensed to Partner RedHill – RHB-107 (upamostat) Evaluation in New Indications RHB-107 – UpA/S1 serine protease inhibitor Potential first-in-class small molecule targeting targeting cancer, inflammatory lung diseases, and gastrointestinal diseases • So far: Positive Phase II trials in
Slide 22: Outlook & Financials
Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered ATAC projects Outlook & Financials © Heidelberg Pharma AG 22
Slide 23: Operational Outlook
Operational Outlook ATAC technology HDP-101 – next steps planned • Submission of IND (US) and CTA (Germany) • Site activation & First Patient In • Continue biomarker development • Presentation at important Conference American Society of Hematology (ASH) in December 2020 • Presentation of Phase I/II
Slide 24: Financials and Shares
Financials and Shares FYR 2019 9M 2020 Guidance Revised guidance in € m 03/2020 09/2020 Sales revenue and other income 8.0 8.3 8.0 to 10.0 9.0 to 10.0 Operating expenses 18.1 20.7 20.0 to 24.0 26.0 to 28.0 R&D costs 10.9 13.5 - - Operating result (EBIT) (10.1) (12.5) (11.0) to (15.0) (16.0) to (19.0
Slide 25: Financing and Shares
Financing and Shares Financing • €14.4 m gross proceeds from private placement with dievini and selected institutional investors in April 2020 • Cash as of 31 August 2020: € 9.2 m, Cash reach is secured until mid-2021 based on current budget planning including the financing commitment of € 15 millio
Slide 26: Investment Summary
Investment Summary Disruptive first-in-humans mode of action provides high efficacy and potential for unique clinical advantages, including treatment of dormant tumor cells Increased efficacy against 17p deleted and aggressive tumor cells based on biomarker Validated by high quality collaborations (